Compare Ascendis Pharma A/S (ASND) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Ecopetrol SA — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while Ecopetrol SA trades at $15.8 (market cap $29.34B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays a 4.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EC | |
|---|---|---|
Market Cap | $17.74B | $29.34B |
Sector | Health | Energy |
52-Week High | $277.18 | $16.58 |
52-Week Low | $163.32 | $8.29 |
Enterprise Value | $18.11B | $57.13B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Ecopetrol (EC) trades at $15.58, up 1.23% with bullish technical signals from moving averages. The stock shows mixed fundamentals with declining revenue from $159.6B in 2022 to $119.7B in 2025, though maintains stable 8.76% net margins. Recent corporate developments include a $0.66 dividend payment and S&P credit rating affirmation at BB- with stable outlook as of June 17, 2026.
EC presents a cautious opportunity with attractive valuation multiples (P/E 11.1, P/S 0.97) but faces revenue headwinds. Analyst consensus is mixed with 27% buy ratings and $14.63 target below current price. Key risks include energy price volatility and execution challenges amid declining cash flows from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
